Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2016

View Archived Issues

NYMC and Interprotein collaborate on C2 domain-interactive therapeutics

Theranexus obtains funding for development of THN-201

Bayer and Evotec establish 5-year research partnership in kidney disease

Regen BioPharma's NR2F6 modulators show positive preclinical results

Abilita Bio awarded grant from NCI

Takeda and Affilogic establish Nanofitins research collaboration for neurological disorders

NuSirt and OWL Metabolomics partner to develop companion diagnostic for NS-0200

Chromosome 1 variant is associated with increased risk of IFN-beta-induced liver injury

NIH award supports Symbiotix's development of PSA for IBD

Novel model for the development of phages that target pathogenic bacteria

Artios Pharma launched to focus on developing novel DNA damage response cancer therapies

Allergan acquires Akarna Therapeutics

AstraZeneca withdraws MAA for cediranib

Aurigene Discovery Technologies patents PD-1 signaling inhibitors

Sunshine Lake Pharma discloses HCV inhibitors

Eleven Biotherapeutics acquires Viventia Bio

Nanjing Sanhome Pharmaceutical describes PI3Kdelta inhibitors

Medshine Discovery develops CDK4/cyclin D1 and CDK6/cyclin D1 inhibitors

Melinta Therapeutics presents antibacterials

Quest Diagnostics launches Zika antibody test service

EMA grants PRIME scheme access to Bluebird's Lentiglobin and Juno's JCAR-015

Newron re-submits Xadago NDA

Regulus begins phase II trial of RG-012 in Alport syndrome

Takeda presents phase II results for TAK-448 in men with T2D and HH

Kadmon initiates phase II trials of KD-025 in psoriasis and GvHD

FDA approves Janssen Pharmaceuticals' Invokamet XR

Gilead stops phase II/III study of GS-5745 in ulcerative colitis based on DMC review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...